Zentiva (PRIVATE.ZENTIVA)

Overall impact
B (74)

Commentary

Zentiva is a strong overall performer. With a 'B' rating of 74.3 for overall impact (88th percentile compared to all companies), Zentiva ranks 63rd out of 260 industry peers, behind Assembly Biosciences, Piramal Enterprises, Evoke Pharma and 59 others, and ahead of Catalyst Pharmaceuticals, Agios Pharmaceuticals, Pharmaron Beijing H and 194 others. On top material causes for Zentiva's industry (Pharmaceuticals), Zentiva performs well in Child and Maternal Health (95.1 score), Humane Treatment of Animals (92.5), Racial Justice and Civil Rights (94.9) and 21 other causes where it received an 'A' score and performs poorly in Child and Maternal Health (0.0 score), Child and Maternal Health (0.0), Child and Maternal Health (0.0) and 6 other causes where it received a 'D' or 'F' score.
Impact
Cause PRIVATE.ZENTIVA
Peer rank
Overall impact

Log in to view this information

Impact trend

Change in rating for overall impact

Log in to view this information

Company
Founded
1993
Employees
4,800
Sector
Health Care
Industry
Pharmaceuticals
Sub-industry
Pharmaceuticals
SASB industry
Biotechnology & Pharmaceuticals
Headquarters
Czech Republic
Share classes
PRIVATE.ZENTIVA
Description
Zentiva AS is engaged in the development, production, and distribution of generic medicines. It operates in more than 25 European markets. The company’s therapeutic areas include Cardiovascular, Central nervous system, Gastrointestinal and metabolic disorders, Anti-inflammatory and pain, Ophthalmology, Anti-infectives, Urology, Respiratory, Blood disorders, and Oncology.
Material causes
Ethos considers the following causes material for Zentiva, based on its industry sub-industry Pharmaceuticals. Learn more about material causes in our methodology overview.

This information is subject to Ethos' Terms and Conditions, which you can find here.

This information may not be used for corporate financing purposes (including, without limitation, ESG-linked loans, credit facilities, securities or structured products), as a basis for any financial instruments or products (including, without limitation, passively managed funds and index-linked derivative securities) or other products or services, to verify or correct data in any other compilation of data or index, to create any derivative works, nor to create any other data or index (custom or otherwise), without Ethos' prior written permission.

By browsing this site you agree to our use of cookies. Read more.
We use cookies on this site to enhance your user experience. By continuing to browse the site, you are agreeing to our use of cookies. Give me more info.